News

Topcon Medical Systems has released its new KR/RM-800 auto refractor series. The company begins delivering the new products at the end of June.

Regeneron Pharmaceuticals Inc. and Bayer HealthCare reported positive top-line results for aflibercept injection (Eylea) from the phase III MYRROR study in myopic choroidal neovascularization (mCNV).

Ethnic differences in anterior chamber angle anatomy exist and may explain the increased risk for angle-closure glaucoma among Chinese, said Shan C. Lin, MD, professor of ophthalmology and co-director of the glaucoma service, University of California San Francisco School of Medicine.

Eye-care professional across the United States are expected to converge on the nation’s capital for the 2nd Annual Focus on Eye Health National Summit.

Secondary IOL implantation is widely accepted, especially in aphakic patients who have become contact lens intolerant or noncompliant. A number of studies on the topic, mostly from Western countries, have had small sample sizes, and the safety and efficacy of the procedure have not been well studied.

ThromboGenics NV has started research and development of innovative protein therapeutics to address a biologic target implicated in a range of diabetic eye diseases, such as diabetic macular edema.

Transitions Optical Inc. continues to support the American Diabetes Association (ADA) by educating consumers about the importance of regular eye care for the early detection and treatment of diabetes during ADA Expo events.

Prevent Blindness America (PBA) along with its affiliates and partners is joining forces to promote a national “AMD: Awareness Makes a Difference” program to educate adults on the disease and the steps that can be taken, including regular eye exams, to protect their vision.

Now an ophthalmologist, she travels the world helping restore sight to the needy

Findings point to improvements in cleaning procedures, less reuse of cannulas

Higher-concentration drug statistically superior to vehicle for achieving resolution of inflammation

Patient comfort, minimal foreign body sensation support routine use for cataract surgery

Phase IIb, III data show anti-inflammatory/mydriatic agent reduces miosis

Loteprednol etabonate 0.5% provides enhanced safety, efficacy, comfort for refractive surgery

How one practice uses protocol, point-of-care testing for effective diagnosis, management

PRK less invasive; procedure more compatible in patients with suspected keratoconus

Study shows better reproducibility with devices dedicated to standardizing capsulorhexis

Biologic corneal bandage controls inflammation and promotes regenerative healing

What keeps everyone up at night? Disillusionment with continual change

Now an ophthalmologist, she travels the world helping restore sight to the needy

Market as predictor of demand for U.S. ophthalmologists?

Removing beta-carotene, adding lutein/zeaxanthin show clear patient benefits

Effectiveness depends on stage of the disease, mechanism of angle closure

LASIK results are good. Studies using current LASIK platforms routinely show 20/20 in excess of 80% of eyes and a high degree of satisfaction in 95% of patients. With about one million eyes treated annually, LASIK results are so good the U.S. military has accepted the procedure for combat pilots. But what about physicians?

While the control rate for uveal melanoma approaches 100%, disease-related mortality for this cancer has remained essentially unchanged over the past eight decades. According to Thomas M. Aaberg Jr., MD, identifying patients at greatest risk for metastasis and providing them with prophylactic treatment are key to altering mortality outcomes in the future.

Despite the damaging effects of ultraviolet radiation (UV) to the eyes and vision, 40% of adults in the United States say they do not wear sunglasses while outdoors.

The FDA has approved Bausch + Lomb’s Trulign lens, a toric posterior chamber IOL that corrects for astigmatism and has the capacity to deliver improved vision across a natural range of focus.

Justine Smith, FRANZCO, PhD, FARVO, of Flinders University, Adelaide, South Australia, is the new president of the Association for Research in Vision and Ophthalmology.

Valeant Pharmaceuticals International Inc. and Bausch + Lomb Holdings Inc. have entered into a definitive agreement, under which Valeant will acquire Bausch + Lomb.